{"id":57769,"date":"2023-07-19T13:04:24","date_gmt":"2023-07-19T11:04:24","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/vitrivax-awarded-29m-dod-contract-to-fund-vaccine-research\/"},"modified":"2023-07-19T13:04:24","modified_gmt":"2023-07-19T11:04:24","slug":"vitrivax-awarded-29m-dod-contract-to-fund-vaccine-research","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/vitrivax-awarded-29m-dod-contract-to-fund-vaccine-research\/","title":{"rendered":"VitriVax Awarded $29M DoD Contract to Fund Vaccine Research"},"content":{"rendered":"
\n

\nFive-year contract to develop a single-injection, thermostable vaccine for melioidosis and glanders<\/i><\/p>\n

BOULDER, Colo.–(BUSINESS WIRE)–VitriVax Inc., a formulation technology company, has been awarded a $29M five-year contract by the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe overall objective of the research proposal titled \u201cOptimization and Production of Single-Shot Vaccines for Melioidosis and Glanders\u201d is to apply VitriVax\u2019s single-shot and thermostabilization technology (ALTA\u2122) to the lead B. pseudomallei<\/i> (Bp) vaccine candidate, which is currently a three-dose regimen, with the goal of developing a single injection, thermostable vaccine formulation to protect against melioidosis and glanders. The project will focus on preclinical studies and development of Good Manufacturing Practice protocols, working toward an Investigational New Drug Application submission.<\/p>\n

\n\u201cWe are excited about the opportunity to partner with DTRA and researchers at the University of Nevada, Reno to bring our technology to a class of vaccines that will benefit both military personnel and the general population in regions where the disease is endemic,\u201d said Kimberly D. Erickson, Ph.D., VitriVax\u2019s Vice President of Operations and Principal Investigator.<\/p>\n

\nVitriVax has built a strong research team consisting of formulation and analytical scientists, as well as particle engineers and manufacturing experts. They have strategically partnered with the University of Nevada, Reno and the Latham BioPharm Group, Inc., to compile a support team of industry veterans with years of Bp vaccine development, government program management experience, and government contract compliance knowledge.<\/p>\n

\nAbout VitriVax<\/b><\/p>\n

\nVitriVax, headquartered in Boulder, CO, has engineered its proprietary Atomic Layering Thermostable Antigen and Adjuvant (ALTA\u2122) technology platform to enable thermostable, single-shot vaccines across a broad range of indications, while maintaining or potentially even enhancing the immune response of vaccines. ALTA\u2122 can be applied to a wide variety of vaccine antigens and adjuvants to protect against thermal and chemical degradation and enable controlled release, incorporating prime doses + additional booster doses in a single-shot administration. These technologies may also facilitate co-formulation of multiple, otherwise incompatible, antigens in a single injection.<\/p>\n

Contacts<\/b> <\/p>\n

\nVitriVax<\/b>
Media Relations
\n
Anne King
\n
+1 (860) 415-3290
\n
anne.king@kingpr.net<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Five-year contract to develop a single-injection, thermostable vaccine for melioidosis and glanders BOULDER, Colo.–(BUSINESS WIRE)–VitriVax Inc., a formulation technology company, has been awarded a $29M five-year contract by the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense. The overall objective of the research proposal titled \u201cOptimization and Production of Single-Shot … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-57769","6":"format-standard","7":"category-industry"},"yoast_head":"\nVitriVax Awarded $29M DoD Contract to Fund Vaccine Research - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/vitrivax-awarded-29m-dod-contract-to-fund-vaccine-research\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VitriVax Awarded $29M DoD Contract to Fund Vaccine Research - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Five-year contract to develop a single-injection, thermostable vaccine for melioidosis and glanders BOULDER, Colo.–(BUSINESS WIRE)–VitriVax Inc., a formulation technology company, has been awarded a $29M five-year contract by the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense. The overall objective of the research proposal titled \u201cOptimization and Production of Single-Shot ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/vitrivax-awarded-29m-dod-contract-to-fund-vaccine-research\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-19T11:04:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230717408346\/en\/1842896\/21\/VitriVax_New_Logo_JPG.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vitrivax-awarded-29m-dod-contract-to-fund-vaccine-research\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vitrivax-awarded-29m-dod-contract-to-fund-vaccine-research\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"VitriVax Awarded $29M DoD Contract to Fund Vaccine Research\",\"datePublished\":\"2023-07-19T11:04:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vitrivax-awarded-29m-dod-contract-to-fund-vaccine-research\\\/\"},\"wordCount\":357,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vitrivax-awarded-29m-dod-contract-to-fund-vaccine-research\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230717408346\\\/en\\\/1842896\\\/21\\\/VitriVax_New_Logo_JPG.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vitrivax-awarded-29m-dod-contract-to-fund-vaccine-research\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vitrivax-awarded-29m-dod-contract-to-fund-vaccine-research\\\/\",\"name\":\"VitriVax Awarded $29M DoD Contract to Fund Vaccine Research - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vitrivax-awarded-29m-dod-contract-to-fund-vaccine-research\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vitrivax-awarded-29m-dod-contract-to-fund-vaccine-research\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230717408346\\\/en\\\/1842896\\\/21\\\/VitriVax_New_Logo_JPG.jpg\",\"datePublished\":\"2023-07-19T11:04:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vitrivax-awarded-29m-dod-contract-to-fund-vaccine-research\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vitrivax-awarded-29m-dod-contract-to-fund-vaccine-research\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vitrivax-awarded-29m-dod-contract-to-fund-vaccine-research\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230717408346\\\/en\\\/1842896\\\/21\\\/VitriVax_New_Logo_JPG.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230717408346\\\/en\\\/1842896\\\/21\\\/VitriVax_New_Logo_JPG.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vitrivax-awarded-29m-dod-contract-to-fund-vaccine-research\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"VitriVax Awarded $29M DoD Contract to Fund Vaccine Research\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"VitriVax Awarded $29M DoD Contract to Fund Vaccine Research - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/vitrivax-awarded-29m-dod-contract-to-fund-vaccine-research\/","og_locale":"en_US","og_type":"article","og_title":"VitriVax Awarded $29M DoD Contract to Fund Vaccine Research - Pharma Trend","og_description":"Five-year contract to develop a single-injection, thermostable vaccine for melioidosis and glanders BOULDER, Colo.–(BUSINESS WIRE)–VitriVax Inc., a formulation technology company, has been awarded a $29M five-year contract by the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense. The overall objective of the research proposal titled \u201cOptimization and Production of Single-Shot ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/vitrivax-awarded-29m-dod-contract-to-fund-vaccine-research\/","og_site_name":"Pharma Trend","article_published_time":"2023-07-19T11:04:24+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230717408346\/en\/1842896\/21\/VitriVax_New_Logo_JPG.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/vitrivax-awarded-29m-dod-contract-to-fund-vaccine-research\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/vitrivax-awarded-29m-dod-contract-to-fund-vaccine-research\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"VitriVax Awarded $29M DoD Contract to Fund Vaccine Research","datePublished":"2023-07-19T11:04:24+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/vitrivax-awarded-29m-dod-contract-to-fund-vaccine-research\/"},"wordCount":357,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/vitrivax-awarded-29m-dod-contract-to-fund-vaccine-research\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230717408346\/en\/1842896\/21\/VitriVax_New_Logo_JPG.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/vitrivax-awarded-29m-dod-contract-to-fund-vaccine-research\/","url":"https:\/\/pharma-trend.com\/en\/vitrivax-awarded-29m-dod-contract-to-fund-vaccine-research\/","name":"VitriVax Awarded $29M DoD Contract to Fund Vaccine Research - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/vitrivax-awarded-29m-dod-contract-to-fund-vaccine-research\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/vitrivax-awarded-29m-dod-contract-to-fund-vaccine-research\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230717408346\/en\/1842896\/21\/VitriVax_New_Logo_JPG.jpg","datePublished":"2023-07-19T11:04:24+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/vitrivax-awarded-29m-dod-contract-to-fund-vaccine-research\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/vitrivax-awarded-29m-dod-contract-to-fund-vaccine-research\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/vitrivax-awarded-29m-dod-contract-to-fund-vaccine-research\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230717408346\/en\/1842896\/21\/VitriVax_New_Logo_JPG.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230717408346\/en\/1842896\/21\/VitriVax_New_Logo_JPG.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/vitrivax-awarded-29m-dod-contract-to-fund-vaccine-research\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"VitriVax Awarded $29M DoD Contract to Fund Vaccine Research"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/57769","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=57769"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/57769\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=57769"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=57769"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=57769"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}